Drug Detail
Information about BKM120 + MEK162
Generic Name |
||
|---|---|---|
IND |
BKM120 + MEK162 | |
Brand Name (US) |
||
Manufacturer |
Novartis | |
Drug Type |
Kinase inhibitor | |
Delivery |
Oral | |
Approval Status |
Phase 1 | |
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block KIT Signal Path | |
Drug Category |
PI3K inhibitor + MEK inhibitor | |
Links |
|
Trials of this drug |
|
|
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients |
Trial results |
|
Search for this drug/combination in: